It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Karyopharm Therapeutics Inc (KPTI) USD0.0001

Sell:$9.33 Buy:$9.34 Change: $0.24 (2.64%)
Market closed |  Prices as at close on 18 May 2021 | Switch to live prices |
Change: $0.24 (2.64%)
Market closed |  Prices as at close on 18 May 2021 | Switch to live prices |
Change: $0.24 (2.64%)
Market closed |  Prices as at close on 18 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Karyopharm Therapeutics Inc. is an oncology-focused pharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. Its selective inhibitor of nuclear export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Its lead compound, XPOVIOTM (selinexor), received accelerated approval from the Food and Drug Administration (FDA), in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. Its XPOVIO is an oral SINE compound, which blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. It is also focused on developing treatments for other diseases, such as Hematologic Malignancies and Solid Tumor Malignancies.

Contact details

85 Wells Ave
United States
+1 (617) 6580600

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$689.35 million
Shares in issue:
75.09 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Richard Paulson
    President, Chief Executive Officer, Director
  • Michael Kauffman
    Co-Founder, Director
  • Michael Mason
    Chief Financial Officer, Senior Vice President, Treasurer
  • Ran Frenkel
    Executive Vice President, Chief Development Officer
  • Tanya Lewis
    Executive Vice President, Chief Regulatory Affairs and Strategic Operations
  • Jatin Shah
    Executive Vice President, Chief Medical Officer
  • Michael Mano
    Senior Vice President, General Counsel, Company Secretary
  • Stephen Mitchener
    Senior Vice President, Chief Business Officer
  • Sharon Shacham
    Chief Scientific Officer
  • John Demaree
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.